Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Ivermectin in Covid-19: Review of the Current Evidence


Affiliations
1 Senior Director and Head, BLK Centre for Chest & Respiratory diseases, BLK Super Speciality Hospital, New Delhi, India
2 Senior Consultant and Head, Department of Interventional Pulmonology, Respiratory & Sleep Medicine, Manipal Hospitals, New Delhi, India
3 Senior Consultant, Critical Care & Internal Medicine, Fortis Escorts Hospital, Jaipur, India
4 Senior Consultant & Head- Internal Medicine & Diabetology. Yatharth Super Speciality Hospital, Greater Noida, India
5 Consultant, Institute of Critical Care Medicine, Sir Ganga Ram Hospital, New Delhi, India
6 Senior Consulting Physician, Arpan Sugar Clinic, Bilaspur, India
7 Department of Pulmonary Medicine, AIIMS, Raipur, India
8 Department of Medical Affairs, Macleods Pharmaceuticals Ltd., Mumbai, India
     

   Subscribe/Renew Journal


The COVID‑19 pandemic has gripped the world in fear with more than 109 million cases and more than 2.4 million deaths as of 16th February 2021. After US, India has the second highest number of cases in the world. A pandemic of this scale has clearly become an unmet medical need warranting research on effective pharmaco-therapeutic agents. Given the time constraints, existing drugs have been repurposed to fill in the gap. Ivermectin is an FDA-approved broad spectrum antiparasitic agent. It is enlisted in the core list of WHO Model List of Essential Medicine 2019. Ivermectin is economical, easily available and safe without any major side effects. Recent research has shown that Ivermectin possesses strong anti-viral properties. It can also be safely combined with other repurposed drugs for Covid-19. Here, we review mechanism of action and current scientific evidence of Ivermectin in treatment and prophylaxis of Covid-19. A number of ongoing clinical trials are evaluating the drug further in the treatment and prophylaxis of Covid-19. Based on the current clinical evidence in treatment and prophylaxis, Indian Experts’ consensus and recommendations by multiple Indian state governments, Ivermectin may effectively and safely add to the current armamentarium of Indian clinicians involved in the care and management of Covid-19 patients.

Keywords

Ivermectin, Covid-19. SARS-CoV-2.
Subscription Login to verify subscription
User
Notifications
Font Size



  • Ivermectin in Covid-19: Review of the Current Evidence

Abstract Views: 341  |  PDF Views: 1

Authors

Sandeep Nayar
Senior Director and Head, BLK Centre for Chest & Respiratory diseases, BLK Super Speciality Hospital, New Delhi, India
Puneet Khanna
Senior Consultant and Head, Department of Interventional Pulmonology, Respiratory & Sleep Medicine, Manipal Hospitals, New Delhi, India
Pankaj Anand
Senior Consultant, Critical Care & Internal Medicine, Fortis Escorts Hospital, Jaipur, India
N. K. Soni
Senior Consultant & Head- Internal Medicine & Diabetology. Yatharth Super Speciality Hospital, Greater Noida, India
Niraj Tyagi
Consultant, Institute of Critical Care Medicine, Sir Ganga Ram Hospital, New Delhi, India
Yashwant Dubey
Senior Consulting Physician, Arpan Sugar Clinic, Bilaspur, India
Siddharth Patanwar
Department of Pulmonary Medicine, AIIMS, Raipur, India
Aaditi Phadke
Department of Medical Affairs, Macleods Pharmaceuticals Ltd., Mumbai, India
Parthasarathy Muralidharan
Department of Medical Affairs, Macleods Pharmaceuticals Ltd., Mumbai, India
Amit Qamra
Department of Medical Affairs, Macleods Pharmaceuticals Ltd., Mumbai, India

Abstract


The COVID‑19 pandemic has gripped the world in fear with more than 109 million cases and more than 2.4 million deaths as of 16th February 2021. After US, India has the second highest number of cases in the world. A pandemic of this scale has clearly become an unmet medical need warranting research on effective pharmaco-therapeutic agents. Given the time constraints, existing drugs have been repurposed to fill in the gap. Ivermectin is an FDA-approved broad spectrum antiparasitic agent. It is enlisted in the core list of WHO Model List of Essential Medicine 2019. Ivermectin is economical, easily available and safe without any major side effects. Recent research has shown that Ivermectin possesses strong anti-viral properties. It can also be safely combined with other repurposed drugs for Covid-19. Here, we review mechanism of action and current scientific evidence of Ivermectin in treatment and prophylaxis of Covid-19. A number of ongoing clinical trials are evaluating the drug further in the treatment and prophylaxis of Covid-19. Based on the current clinical evidence in treatment and prophylaxis, Indian Experts’ consensus and recommendations by multiple Indian state governments, Ivermectin may effectively and safely add to the current armamentarium of Indian clinicians involved in the care and management of Covid-19 patients.

Keywords


Ivermectin, Covid-19. SARS-CoV-2.

References